Clinical Context
A typical patient is a 42-year-old with moderate to severe Crohn disease or rheumatoid arthritis experiencing inadequate response to conventional therapy who presents to an infusion center for biologic therapy. The patient has a confirmed order for J1745 (infliximab, brand, 10 mg vial) with dose calculated based on weight (for example, 5 mg/kg given as a 100 mg or 200 mg dose depending on vial count) and scheduled infusion times at weeks 0, 2, and 6 for induction, then every 8 weeks for maintenance. The clinical workflow includes verification of prior authorization and benefit eligibility with payors (for example, Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, Medicare), screening for active infections (including tuberculosis), baseline laboratory testing (CBC, CMP, hepatitis B surface antigen), evaluation for contraindications (active infection, hypersensitivity to murine proteins), IV line placement, premedication as indicated (antihistamines, acetaminophen, corticosteroids), administration of the reconstituted and diluted infliximab infusion over the recommended time (typically 2 hours for first infusion, may be shortened for subsequent infusions per protocol), monitoring for infusion reactions during and for at least 1–2 hours post-infusion, documentation of lot number and expiration for each vial of J1745, and billing of the drug per 10 mg units administered with appropriate modifier(s) reflecting service circumstances. The typical site of service is an outpatient infusion center, hospital outpatient department, or physician office equipped for IV biologic administration. Patient education includes potential adverse effects (infusion reactions, increased infection risk) and instructions to seek urgent care for severe symptoms.
Coding Specifications
| Modifier | Description | When to Use |
|---|
JW | Drug amount discarded/not administered | Use when a portion of the infliximab vial is wasted and documentation of discarded amount is required. |
JZ | No drug administered but billed incorrectly (not typical) | Rarely used; not applicable unless an error results in billing for drug not given. |
QS | (Not in list) | Data not available in the input. |
59 | Distinct procedural service | Use when reporting a separate, distinct service on the same date that is unrelated to infusion. |
52 | Reduced services | Use when a planned portion of the infusion or service is reduced or partially performed. |
53 | Discontinued procedure | Use when the infusion is started but discontinued due to acute reaction. |
76 | (Not in list) | Data not available in the input. |
78 | Unplanned return to OR by same physician following initial service | Not typically applicable to infusion; use only if applicable surgical intervention occurs after infusion-related complication. |
80 | Assistant at surgery | Not applicable for standard infusion; included if surgical assistant services are billed related to complication. |
62 | Two surgeons | Not typically applicable to infusion services. |
KX | Requirement specified (medical necessity) met | Use when payer requires specific documentation of medical necessity for biologic therapy. |
Q6 | Service furnished under a competitive acquisition program | Use if the drug was acquired via a qualifying program and payer requires this modifier. |
JW | Amount discarded/not administered | See above; clinically relevant for single-use vial waste reporting. |
JA | Treatment of an emergency medical condition | Use if infusion was provided during an emergency admission for acute flare. |
| Taxonomy Code | Specialty | Notes |
|---|
208000000X | Allergy & Immunology | Specialists who may prescribe and oversee biologic therapy. |
207RR0500X | Rheumatology | Common specialty managing rheumatoid arthritis and ankylosing spondylitis treated with infliximab. |
207P00000X | Gastroenterology | Common specialty managing Crohn disease and ulcerative colitis treated with infliximab. |
363L00000X | Infusion Therapy | Providers/centers specializing in IV infusion administration. |
207Q00000X | Internal Medicine | Primary care or hospitalists who may initiate or coordinate biologic therapy. |
Note: From the provided modifier list, only the most clinically relevant modifiers (e.g., JW, JZ, 53, 52, 59, KX, Q6, JA) are detailed above. Other listed modifiers are payer- or circumstance-specific and should be used per payer guidelines.